1. Yoshihisa Matsumoto | MEMBER - Laboratory for Zero-Carbon Energy
Feature of Research. Our laboratory aims to elucidate the biological effects of radiation and the biological response to radiation in molecular terms.
Nuclear Energy Division
2. Yoshihisa Matsumoto - Loop (Frontiers)
Director. Primary. Department of Palliative Therapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research. Tokyo, Japan · Researcher. National ...
Loop is the open research network that increases the discoverability and impact of researchers and their work. Loop enables you to stay up-to-date with the latest discoveries and news, connect with researchers and form new collaborations.
3. Updated Guidelines Provide Vital Insights for Pain Management of ...
Dec 20, 2022 · In part 2 of our series on palliative care, expert Dr. Yoshihisa Matsumoto explains why general guides cannot replace therapeutic planning ...
In part 2 of our series on palliative care, expert Dr. Yoshihisa Matsumoto explains why general guides cannot replace therapeutic planning based on careful assessment of an individual patient’s pain.
4. Yoshihisa Matsumoto | Institute of SCIENCE TOKYO Green ...
Among various DNA damages caused by radiation, DNA double-strand breaks (DSBs) are the most serious and key to the effectiveness of cancer therapy. The aim of ...
Science Tokyo GXI's website, which aims to contribute to the construction of a society in harmony with the global environment through its activities as a center for GX research.
5. Research Area - J-SUPPORT
Palliative care for symptoms arising from cancer. Yoshihisa Matsumoto · Hiroto Ishiki / Jun Kako / Tomofumi Miura / Masaki Mori / Saho Wada. Psychosocial and ...
Unincorporated Association J-SUPPORTJapan Supportive, Palliative and Psychosocial Oncology Group
6. Early specialized palliative care for patients with metastatic lung cancer ...
This is the feasibility study of a nurse-led screening ... Yoshihisa Matsumoto ,. Yoshihisa Matsumoto. Department of Palliative Medicine.
This is the feasibility study of a nurse-led screening-triggered palliative care programme integrated into standard cancer treatment even from the early ph
7. DNA-Dependent Protein Kinase in DNA Damage Response
Three Decades and Beyond. Matsumoto, Yoshihisa 1,; Sharma, Mukesh Kumar 1,2 ... is associated with increase in genomic instability and cancer risk. On the ...
tion. DNA-dependent protein kinase (DNA-PK), consisting of DNA-PK catalytic subunit and Ku80-Ku70 heterodimer (Ku), is activated upon binding to the end of double-stranded DNA and acts as the molecular sensor for DSB. While DSB is repaired mainly through homologous recombination and nonhomologous end joining in eukaryotes, DNA-PK is shown to be essential in the latter pathway. Moreover, DNA-PK is reported to be capable of phosphorylating a number of proteins, suggesting versatile functions of DNA-PK in cellular response to DSB. Here, we review the advance in our understanding on DNA-PK in three decades and remaining problems....
8. Yoshihisa Matsumoto, MD - ASCO Meeting Program Guide
It is extremely stressful and difficult for cancer patients to tell their children that they had cancer. However, few small studies have been conducted to ...
Sort by
9. Nurse‐Led Screening‐Triggered Early Specialized Palliative Care ...
Nov 18, 2024 · Correspondence: Yoshihisa Matsumoto (yoshihisa.matsumoto@jfcr.or.jp) ... We recruited patients with newly diagnosed advanced lung cancer.
We aimed to examine the effectiveness of a nurse‐led, screening‐triggered early specialized palliative care intervention program for patients with advanced lung cancer. Patients with advanced lung cancer who underwent initial chemotherapy were ...
10. Department of Palliative Medicine
Department of Palliative Medicine. Yoshihisa Matsumoto, Tomofumi Miura, Yuko ... 7) A survey about burden and distress in cancer patients who have children using ...
Yoshihisa Matsumoto, Tomofumi Miura, Yuko Uehara, Kazuhiro Kosugi, Yuko Usui, Tatsuto Terada, Yujiro Inoue, Maika Natsume, Yajima Yuki Midori, Yasutaka Shimotsuura, Naoki Serizawa, Yohei Kudo, Yukako Hattori, Rie Yamamoto, Ayumi Okizaki Matsumoto, Masako Ikeda, Sachiko Nagatsuma, Yoshiko Tomita
11. Directors - J-SUPPORT
The scope is from cancer diagnosis to end-of-life, and survivorship for ... Yoshihisa Matsumoto. 松本禎久先生. I am in charge of the Supportive and ...
Unincorporated Association J-SUPPORTJapan Supportive, Palliative and Psychosocial Oncology Group
12. OP-8 A feasibility randomized controlled trial comparing opioid ...
Yoshihisa Matsumoto9 and; Eriko Satomi1,3. 1Department of Palliative Medicine ... cancer pain, no randomized controlled trials (RCTs) have been conducted.
Background Cancer pain affects 38–85% of cancer patients, with higher incidence in advanced stages.1 Poorly controlled cancer pain, often with neuropathic elements, presents a significant unmet medical need. Despite various opioid formulations, 47% of physicians report difficulties in managing opioid-refractory pain.2 Methadone has shown superior efficacy to other opioids, such as morphine, especially for neuropathic pain poorly controlled by other opioids.3 Currently, opioid escalation is the standard, but is often inadequate, and although the methadone add-on (AO) method has been reported to be safe and effective for refractory cancer pain, no randomized controlled trials (RCTs) have been conducted. Aims This study aims to explore the feasibility of conducting a double-blind RCT to assess the efficacy and safety of the methadone AO method for opioid escalation in patients with cancer pain. Methods This study is a single-facility, double-blind, parallel-arm RCT. A total of 22 patients will be enrolled between July 2024 and September 2025. Eligible participants are adults with unresectable advanced cancer experiencing refractory cancer pain on an appropriate dose of opioid analgesia (60–300 mg oral morphine equivalent daily dose, OMEDD) and a Karnofsky Performance Status (KPS) >50. Participants will be randomized (1:1) to the methadone AO arm or the standard treatment arm. Evaluations will be conducted at baseline (randomization), day 1, 8, and 15. In the methadone AO arm,...
13. JJCO Awards | Japanese Journal of Clinical Oncology - Oxford Academic
2023 JJCO Paper of the Year. Research policy in supportive care and palliative care for cancer dyspnea. Yoshinobu Matsuda, Takashi Yamaguchi, Yoshihisa ...
14. Yoshihisa Matsumoto Inventions, Patents and Patent Applications ...
With the method for diagnosing cancer according to the present invention, the presence of cancer cells can be investigated, whatever the organ or the cause ...
USPTO patent applications submitted by and patents granted to Yoshihisa Matsumoto
15. Yoshihisa Matsumoto - Papers - researchmap
... Yoshihisa Matsumoto, Kengo Imai … ... Parenting experiences of cancer patients with ... Cancer Dyspnea Is Acceptable to Cancer Patients and Their Relatives.
researchmap is an information sharing platform for the researchers. researchmap is provided by Japan Science and Technology Agency.
